UHPLC-MS/MS Analysis of Cannabidiol and Its Metabolites in Serum of Patients with Resistant Epilepsy Treated with CBD Formulations

UHPLC-MS/MS Analysis of Cannabidiol and Its Metabolites in Serum of Patients with Resistant Epilepsy Treated with CBD Formulations

Cannabidiol (CBD) is a promising therapeutic agent with analgesic, myorelaxant, and anti-epileptic actions. Recently, a purified form of CBD (Epidiolex<sup>®</sup>) has been approved by the European Medicines Agency (EMA) for the treatment of two highly-refractory childhood-onset epileps...

Full description

Bibliographic Details
Main Authors: Sara Malaca, Massimo Gottardi, Federica Pigliasco, Sebastiano Barco, Alessia Cafaro, Elisabetta Amadori, Antonella Riva, Martina Marcenaro, Pasquale Striano, Giuliana Cangemi, Roberta Pacifici, Simona Pichini, Francesco Paolo Busardò
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Pharmaceuticals
Subjects:
cannabinoids
medical cannabis
serum
CBD metabolites
UHPLC-MS/MS
Online Access:https://www.mdpi.com/1424-8247/14/7/630

Internet

https://www.mdpi.com/1424-8247/14/7/630

Similar Items